Meta-analysis · 2004
Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis
Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B (2004). Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. International Journal of Impotence Research. doi:10.1038/sj.ijir.3901172
A meta-analysis of 43 antidepressant studies (1,514 men) found daily paroxetine, clomipramine, sertraline and fluoxetine broadly comparable, with paroxetine delaying ejaculation most; only 18.5% of studies met rigorous design criteria.
Summary
Several antidepressants, especially SSRIs (selective serotonin reuptake inhibitors) and clomipramine, delay ejaculation as a side effect and are used off-label to treat premature ejaculation (PE). This review examined 79 drug studies (3,034 men) published between 1943 and 2003, and meta-analysed 43 SSRI and clomipramine studies (1,514 men) to calculate the percentage increase in intravaginal ejaculatory latency time (IELT).
With daily treatment, paroxetine, clomipramine, sertraline and fluoxetine had broadly comparable overall efficacy, but paroxetine produced the strongest ejaculation delay. Study design mattered a great deal: retrospective questionnaires, subjective reports, single-blind and open studies produced far more variable results than prospective stopwatch measurement. Only eight studies (18.5%) met all evidence-based criteria, such as being randomised, double-blind and using stopwatch timing at each intercourse.
Limitations
The analysis covers studies up to 2003 and pools trials of very uneven quality. Doses, durations and populations varied. It does not address side effects, which are an important consideration with daily SSRIs.
What it means for you
Daily SSRIs can delay ejaculation and are a recognised off-label option, prescribed by a doctor who will weigh side effects and explain how to start and stop safely. This review is also a lesson in reading evidence: poorly designed studies can make any treatment look better or worse than it is.